"Organizations like MMV represent a new way of doing business... This new approach makes the most of the strengths of the private and the public sectors. MMV shows how the market can work for the world’s poorest people."

Melinda Gates, Co-Chair of the Bill & Melinda Gates Foundation, highlighted the crucial need for continued innovation for malaria and succinctly described MMV’s successful partnership model for drug R&D at the at the World Economic Forum Annual Meeting in Davos, Switzerland on 25 January 2007.

Death and disability due to malaria have considerable economic impact in endemic countries - costing Africa US$12 billion in lost GDP every year and consuming 40 percent of all public health spending. Control and prevention of malaria is finally rising in the priority list of world issues that must be tackled if the Millennium Development Goals are to be met. MMV’s success in creating a balanced portfolio of over 20 drug development projects in the last 6 years has been largely due to the generous support provided by the Bill & Melinda Gates Foundation and other foundations, corporate and government donors.

Read the prepared remarks by Melinda French Gates, co-chair.